Alkermes Plc
NASDAQ:ALKS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.01
32.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alkermes Plc
Alkermes Plc
Accounts Receivables
Alkermes Plc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Accounts Receivables
$370.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Accounts Receivables
$112.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
33%
|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Accounts Receivables
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alkermes Plc
Glance View
Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
See Also
What is Alkermes Plc's Accounts Receivables?
Accounts Receivables
370.2m
USD
Based on the financial report for Sep 30, 2024, Alkermes Plc's Accounts Receivables amounts to 370.2m USD.
What is Alkermes Plc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
10%
Over the last year, the Accounts Receivables growth was 9%. The average annual Accounts Receivables growth rates for Alkermes Plc have been 8% over the past three years , 8% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
